2945-08-6

Basic information

• Product Name: Methylp-nitrophenylacetate
• Synonyms: (4-Nitrophenyl)acetic acid methyl ester;2-(p-Nitrophenyl)acetic acid methyl ester;4-Nitrobenzeneacetic acid methyl ester;4-Nitrophenylacetic acid methyl ester;Methyl 2-(4-nitrophenyl)acetate;Methyl 2-(4-nitrophenyl)
• CAS NO: 2945-08-6
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 195.18
• Mol File: 2945-08-6.mol
• Article Data: 62

Chemical Properties

• Melting Point: 52.4-53.3 °C
• Boiling Point: 308.62 °C at 760 mmHg
• Flash Point: 143.86 °C
• Appearance: /
• Density: 1.267 g/cm³
• Vapor Pressure: 0.000673mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methylp-nitrophenylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methylp-nitrophenylacetate(2945-08-6)
• EPA Substance Registry System: Methylp-nitrophenylacetate(2945-08-6)

Safety Data

• Hazardous Substances Data: 2945-08-6(Hazardous Substances Data)

Usage

Appearance

a pale orange oil

Synthesis

4-nitrophenylacetic acid(2.00 g, 11 mmol) was added to a clean carousel tube. Dimethyl carbonate (3 mL, 3.21 g, 35.6 mmol) was added, and the reaction was heated at reflux overnight. The brown solution was allowed to cool, and poured in to aqueous sodium bicarbonate (10%, 10 mL) while stirring. The resulting mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with water and brine (10 mL each), and dried over anhydrous magnesium sulphate. After filtration and evaporation of the solvents, proton NMR analysis showed the product had formed, and none of the precursor acid remained. No further purification was performed. This gave methyl p-nitrophenylacetate as a pale orange oil (1.929 g, 9.89 mmol, 90%)): 1H NMR (400 MHz, CDCl 3 ) δ 8.20 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H, 3.74 (s, 2H), 3.73 (s, 3H).

InChI:InChI=1/C9H9NO4/c1-14-9(11)6-7-2-4-8(5-3-7)10(12)13/h2-5H,6H2,1H3

Upstream product

• 67-56-1 methanol 
• 104-03-0 4-nitrobenzeneacetic acid 
• 50434-36-1 4-nitrophenylacetyl chloride 
• 27888-12-6 dimethylthiocarbamoylsulfanyl-acetic acid methyl ester 
• 98-95-3 nitrobenzene 
• 17277-58-6 methyl (phenylsulfanyl)acetate 
• 4203-31-0 2-diazo-1-(4-nitrophenyl)ethanone 
• 22812-58-4 methyl 2-diazo-2-(4-nitrophenyl)acetate 
• 75-05-8 acetonitrile 
• 100-19-6 (4-nitrophenyl)ethanone 
• 1877-73-2 3-nitro-benzeneacetic acid 
• 1227248-65-8 2-(4-nitrophenyl)-malonic acid t-butyl ester methyl ester 
• 1360788-98-2 2-(4-nitrophenyl)-1-(2,2,6,6-tetramethylpiperidin-1-yl)ethanone 
• 119114-55-5 N-Methoxy-2-(4-nitro-phenyl)-acetamide 

Downstream Products

• 31733-55-8 N-benzyl-2-(4-nitrophenyl)acetamide 
• 28899-11-8 ethyl 2-(4-nitrophenyl)-2-oximinoacetate 
• 129852-16-0 2-(4-Nitro-phenyl)-pentanedioic acid dimethyl ester 
• 92872-41-8 2,4,4'-Trinitro-diphenylessigsaeure-aethylester 
• 23848-97-7 2-(4-nitro-phenyl)-5t-phenyl-penta-2t,4-dienoic acid 
• 25169-78-2 2-(4-nitro-phenyl)-5-phenyl-penta-2,4-dienoic acid methyl ester 
• 6321-12-6 2-(4-nitrophenyl)acetamide 
• 340188-33-2 Methyl hydroxyimino-4-nitrophenylacetate 
• 85259-33-2 bromo-(4-nitrophenyl)acetic acid methyl ester 
• 876385-77-2 3-(3,4-dimethoxy-phenyl)-2-(4-nitro-phenyl)-propionic acid methyl ester 
• 259542-49-9 N-{[4-(4-aminophenyl)-5-oxo-2-hydroisoxazol-2-yl]methyl}acetamide 
• 850405-42-4 1-(4-nitro-phenyl)-2-phenyl-cycloprop-2-enecarboxylic acid methyl ester 
• 2874-44-4 (4-nitro-phenyl)-acetic acid benzylidenehydrazide 

Relevant articles and documents

SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS

The disclosure relates to a series of substituted imidazolecarboxamide compounds of formula I as BTK (Bruton's Tyrosine Kinase) inhibitors, and the methods of using the same for the treatment of autoimmune disease, inflammatory disease, cancer and potenti

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase

Renewed interest in covalent inhibitors of enzymes implicated in disease states has afforded several agents targeted at protein kinases of relevance to cancers. We now report the design, synthesis and biological evaluation of 6-ethynylpurines that act as covalent inhibitors of Nek2 by capturing a cysteine residue (Cys22) close to the catalytic domain of this protein kinase. Examination of the crystal structure of the non-covalent inhibitor 3-((6-cyclohexylmethoxy-7H-purin-2-yl)amino)benzamide in complex with Nek2 indicated that replacing the alkoxy with an ethynyl group places the terminus of the alkyne close to Cys22 and in a position compatible with the stereoelectronic requirements of a Michael addition. A series of 6-ethynylpurines was prepared and a structure activity relationship (SAR) established for inhibition of Nek2. 6-Ethynyl-N-phenyl-7H-purin-2-amine [IC50 0.15 μM (Nek2)] and 4-((6-ethynyl-7H-purin-2-yl)amino)benzenesulfonamide (IC50 0.14 μM) were selected for determination of the mode of inhibition of Nek2, which was shown to be time-dependent, not reversed by addition of ATP and negated by site directed mutagenesis of Cys22 to alanine. Replacement of the ethynyl group by ethyl or cyano abrogated activity. Variation of substituents on the N-phenyl moiety for 6-ethynylpurines gave further SAR data for Nek2 inhibition. The data showed little correlation of activity with the nature of the substituent, indicating that after sufficient initial competitive binding to Nek2 subsequent covalent modification of Cys22 occurs in all cases. A typical activity profile was that for 2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide [IC50 0.06 μM (Nek2); GI50 (SKBR3) 2.2 μM] which exhibited >5-10-fold selectivity for Nek2 over other kinases; it also showed > 50% growth inhibition at 10 μM concentration against selected breast and leukaemia cell lines. X-ray crystallographic analysis confirmed that binding of the compound to the Nek2 ATP-binding site resulted in covalent modification of Cys22. Further studies confirmed that 2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide has the attributes of a drug-like compound with good aqueous solubility, no inhibition of hERG at 25 μM and a good stability profile in human liver microsomes. It is concluded that 6-ethynylpurines are promising agents for cancer treatment by virtue of their selective inhibition of Nek2. This journal is

Rational design of novel irreversible inhibitors for human arginase

Parasites have developed a variety of strategies for invading hosts and escaping their immune response. A common mechanism by which parasites escape nitric oxide (NO) toxicity is the activation of host arginase. This activation leads to a depletion of L-arginine, which is the substrate for NO synthase, resulting in lower levels of NO and increased production of polyamines that are necessary for parasite growth and differentiation. For this reason, small molecule inhibitors for arginase show promise as new anti-parasitic chemotherapeutics. However, few arginase inhibitors have been reported. Here, we describe the discovery of novel irreversible arginase inhibitors, and their characterization using biochemical, kinetic, and structural studies. Importantly, we determined the site on human arginase that is labeled by one of the small molecule inhibitors. The tandem mass spectra data show that the inhibitor occupies the enzyme active site and forms a covalent bond with Thr135 of arginase. These findings pave the way for the development of more potent and selective irreversible arginase inhibitors.